Zhongji Innolight's shares surged after receiving approval for a major Hong Kong listing worth up to $8 billion, potentially the city's largest this year, as the Chinese optical transceivers firm gauges investor interest.
Chinese humanoid startup LimX Dynamics has raised $200 million in a pre-IPO round, valuing it at $2.21 billion, and plans to list in Hong Kong. The move comes amid a surge in China's humanoid AI sector, with over 100 companies and significant investment growth.
Kazakhstan Temir Zholy's former CEO announced plans for a triple listing in Hong Kong, London, and Kazakhstan by year-end. Hong Kong's exchange anticipates more international issuers in late 2026/2027, with companies seeking favorable market sentiment.
Shenzhen-based Luxshare, a key Apple supplier, has secured regulatory approval for a Hong Kong listing after receiving the green light from the China Securities Regulatory Commission. The company reported a 24% revenue surge to 332 billion yuan and a 24% net profit increase to 16.6 billion yuan in 2025.
Two major Chinese MLCC suppliers, Chaozhou Three-Circle and Jiangsu Boqian New Materials, are pursuing Hong Kong listings to capitalize on surging global demand for MLCCs driven by AI infrastructure growth.
Chinese lithography firm CFMEE plans a Hong Kong IPO next week, aiming to raise up to $410 million to fund strategic investments, R&D, and capacity expansion as China pursues semiconductor self-sufficiency.
Shanghai-based GPU designer MetaX announced plans for a Hong Kong listing, aiming to raise capital for R&D, expansion, and strategic investments. The proposed H-share offering, representing up to 5% of enlarged capital, follows its recent debut on Shanghai's Star Market.
AI developers MiniMax Group and Knowledge Atlas Technology are listing in Hong Kong before pursuing mainland China stock offerings. This strategy aims to establish international valuations and attract global investors.
Eight mainland China-based companies, including five biotech firms, passed listing hearings on the Hong Kong stock market in April. Metis, founded in 2020 in Hangzhou, uses three proprietary AI platforms to design drug delivery systems. Its revenue surged to 105 million yuan in 2025 from 1.48 million yuan in 2024, while net loss narrowed to 391.8 million yuan. Its leading drug candidate MTS-004 for pseudobulbar affect has completed phase three trials.
